DigestRedComo funciona
Red
/
Empresas
Au
No verificado

Autobahn Therapeutics

Sobre qué escribimos

BiotecnologíaEventosFarmacéuticaMedicina - VariosSalud

10 Comunicados de prensa

Ver todos los comunicados de prensa
10/11/2025
Biotecnología
Psiquiatría
Salud
Farmacéutica
Eventos
Autobahn Therapeutics to Participate in 2025 Jefferies London Healthcare Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
08/07/2025
Psiquiatría
Salud
Ciencia
Farmacéutica
Biotecnología
Eventos
Autobahn Therapeutics to Participate in Evercore’s Emerging Private Biotech Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
27/05/2025
Eventos
Biotecnología
Psiquiatría
Salud
Farmacéutica
Autobahn Therapeutics to Participate in Jefferies Global Healthcare Conference
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
23/05/2025
Eventos
Industria
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Autobahn Therapeutics Announces Presentation of ABX-002 Phase 1 Clinical Results at the 2025 ASCP Annual Meeting
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
08/01/2025
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
Autobahn Therapeutics Announces Initiation of Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
12/11/2024
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Eventos
Finanzas
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
22/10/2024
Industria
Psiquiatría
Salud
Higiene alimentaria
Medicina - Varios
Farmacéutica
Biotecnología
Autobahn Therapeutics Announces FDA Clearance of IND Application for ABX-002 as an Adjunctive Treatment for Bipolar Depression
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
16/09/2024
Industria
Biotecnología
Psiquiatría
Salud
Farmacéutica
Medicina - Varios
Autobahn Therapeutics Announces Initiation of its AMPLIFY Phase 2 Trial of ABX-002 as an Adjunctive Treatment for Major Depressive Disorder
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
10/09/2024
Eventos
Biotecnología
Farmacéutica
Comunicación
Sanidad
Salud
Medicina - Varios
Autobahn Therapeutics to Participate in Multiple Upcoming Investor Conferences
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0
24/07/2024
Psiquiatría
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Autobahn Therapeutics Completes Oversubscribed $100 Million Series C Financing to Advance Pipeline of Novel Therapeutics for Depression and Other CNS Disorders
Fuente
Autobahn Therapeutics
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0